Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.
about
A New Strategy for Deleting Animal drugs from Traditional Chinese Medicines based on Modified Yimusake Formula.A blood screening test for Alzheimer's diseaseParallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons.2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity).Fit-for-purpose biomarker immunoassay qualification and validation: three case studies.Commercial biomarker assays: friend and foe.Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities.Addressing the challenges of biomarker calibration standards in ligand-binding assays: a European Bioanalysis Forum perspective.The Human Plasma Proteome Draft of 2017: Building on the Human Plasma PeptideAtlas from Mass Spectrometry and Complementary Assays.Multiplex Immunoassay Profiling of Serum in Psychiatric Disorders.The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease.Multiplex Immunoassay Profiling.Biomarker measurements: how far have we come and where are we heading?miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease.Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias
P2860
Q33685427-131CA8E2-62F6-4FEA-8294-B3932F54AA71Q37085325-3EC68F08-F42A-4454-B344-9FBD2FC86826Q38665209-13B914CD-4BCC-4512-AB95-A966BFDCB1C9Q39010884-4E3DA612-FDFA-4EB2-B955-492DC4651148Q39315816-7E678CD6-00BD-44E5-9701-AF92A65D6E83Q39321514-46C17D1B-3EF9-4FD2-9814-54C18F53BE13Q40054055-30BA047D-CE51-40F8-88A4-5B9DF2ADB83DQ47748457-21B0005F-380C-447B-958D-1F8F213B6470Q47761810-AB5753D7-690A-48EC-AB90-6A87D377DF4FQ47763299-4369FA61-A8A8-4508-B086-3306173FDB4FQ50532647-783AC647-8967-445B-A925-8A2ED6CD02DBQ51298251-0AD3AF56-BC5E-439E-BC77-1A88F0E82470Q51322752-480D5494-96AE-4550-BD8D-4C7AAE379D95Q52801531-3D27831E-8ACB-43AF-8915-412E64D9D2BEQ58779295-7FFEC7DA-3952-418B-B6A2-72DD9C8A6370
P2860
Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Recommendations for Use and Fi ...... ing Assays in Drug Development
@nl
Recommendations for Use and Fi ...... ng Assays in Drug Development.
@ast
Recommendations for Use and Fi ...... ng Assays in Drug Development.
@en
type
label
Recommendations for Use and Fi ...... ing Assays in Drug Development
@nl
Recommendations for Use and Fi ...... ng Assays in Drug Development.
@ast
Recommendations for Use and Fi ...... ng Assays in Drug Development.
@en
prefLabel
Recommendations for Use and Fi ...... ing Assays in Drug Development
@nl
Recommendations for Use and Fi ...... ng Assays in Drug Development.
@ast
Recommendations for Use and Fi ...... ng Assays in Drug Development.
@en
P2093
P2860
P3181
P1433
P1476
Recommendations for Use and Fi ...... ng Assays in Drug Development.
@en
P2093
Andreas Jeromin
Bill Nowatzke
Carol Gleason
Darshana Jani
Flora Berisha
John Allinson
Kyra J Cowan
Laurie Stephen
Masood U Khan
Paul Rhyne
P2860
P2888
P3181
P356
10.1208/S12248-015-9820-Y
P407
P577
2015-09-16T00:00:00Z
P6179
1043648848